Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
Tuesday, September 28, 2021 11:09:03 AM
"...the Company disputes the underlying basis for these (plural) amounts and notified Dr. Menon in November 2019 of the Company’s intent not to pay them."
"Contingent Liability" is not an accrued liability... it's a potential liability...IN DISPUTE, AS STATED...but must be listed.
IMO...The reporting of it also reveals the defense against the claim...LEO obviously has determined that Menon went hog wild on this own "research" WITHOUT PRIOR APPROVAL...
Even if approved (which obviously they were not, since if so, the language would not have been included in the K), oftentimes...Billings times and services are not documented properly and are subject to billing abuses...
This happens all the time with large wall street Law Firms overbilling...A challenge to a Legal Billings Invoice inevitably leads
to settlement...often times 30-50%...(based on the billing of associates time for over 24 hours in a day period...a little evidence of billing abuse) AN in the event of "prior approval" required...the INVOICE GOES TO ZERO...
IMO...Menon knows it, ergo...no suit. Salary combined in same "claim"...renders it subject resolving both disputes together...unless he severs salary claim.
Why not sue for salary? Simple...that too could be in the dispute...if he was off doing research not authorized as a Rogue Employee...the company's salary "obligation" to him is questionable. Why pay hundreds of thousands $100-$200k in trying to enforce a "claim" when there are likely material issues with the claim. Better to make a demand and wait for the company to get a windfall and collect on a "nuisance claim".
But likely he knows the value of the intellectual property and progress of Brilacidin and K...why put pressure on his stock? Why try to damage his "investment"
IMO he is OBVIOUSLY A LONG...on IPIX!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM